Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Cosmetics

  • Print
  • Share
  • E-mail
-

BSE and Cosmetics: FDA Risk Assessment and Management Perspectives - Slide 25. BSE/ v-CJD: OCAC Role In Process of BSE Risk Analysis- I

December 7, 2006

First  |  ← Previous  |  Slide 25 of 45  |  Next →  |  Last  |  Index

Slide 25. BSE/ v-CJD: OCAC Role In Process of BSE Risk Analysis- I - See text below

BSE/ v-CJD: OCAC Role In Process of BSE Risk Analysis- I

  • 1992 - Education and Outreach
    • Intra-Agency OCAC-sponsored Seminar by CVM
  • Guidance to Industry
    • 1994, 1996 - "Letters to Manufacturers of FDA-Regulated Products (Dietary Supplements and Cosmetics)"
  • FDA TSE Advisory Committee (TSEAC)
    • OCAC Participation in FDA Inter-Center TSE Working Group on Tallow (mid 1990s)
    • OCAC Presentation on Tallow to FDA-TSEAC (April 1998)
-
-